PT968722E - Vacina viva melhorada contra brsv. - Google Patents

Vacina viva melhorada contra brsv. Download PDF

Info

Publication number
PT968722E
PT968722E PT99115633T PT99115633T PT968722E PT 968722 E PT968722 E PT 968722E PT 99115633 T PT99115633 T PT 99115633T PT 99115633 T PT99115633 T PT 99115633T PT 968722 E PT968722 E PT 968722E
Authority
PT
Portugal
Prior art keywords
virus
adjuvants
vet
adjuvant
immunity
Prior art date
Application number
PT99115633T
Other languages
English (en)
Inventor
Hsien-Jue Chu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PT968722E publication Critical patent/PT968722E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (5)

  1. ΡΕ968722 1 REIVINDICAÇÕES 1. Utilização de um Vírus Sincitial Respiratório de Bovinos modificado vivo e de um ou mais adjuvantes em combinação com um ou mais estabilizadores, veículos e adjuvantes aceitáveis do ponto de vista farmacêutico, seleccionados de entre os adjuvantes que proporcionem uma resposta imunológica multifacetada contra o BRSV modificado, sendo os adjuvantes referidos seleccionados de entre aqueles que proporcionem imunidade mediada por células e imunidade local (IgA segregado) e que para além disso sejam elementos do conjunto constituído por: esqualano e o esqualeno (ou outros óleos de origem animal); copolímeros em blocos, de preferência Pluronic® (L121); Saponina; detergentes ou tensioactivos não iónicos, de preferência mono-oleato de polioxietileno(20)-sorbitano Tween®- -80; Quil® A, óleos minerais, de preferência Drakeol® ou Marcol®, óleos vegetais; adjuvantes provenientes de Corynebacterium como por exemplo de Corynebacterium parvum; adjuvantes provenientes de Propionibacterium, de preferência de Propionibacterium acne; Mycobacterium bovis (Bacíllus Calmette e Guerinn, ou BCG); interleuquinas seleccionadas de entre a interleuqina 2 e a interleuquina-12; monoquinas, de preferência a interleuquina 1; factor de necrose tumoral; interferões de preferência interferões gama; combinações de saponina com hidróxido de alumínio ou 2 ΡΕ968722 de Quil® com hidróxido de alumínio; lipossomas; adjuvante iscom; extracto de paredes celulares de micobactérias; glicopéptidos sintéticos, de preferência dipéptidos muramílicos ou outros derivados; Avridina; Lípido A; sulfato de dextrano; DEAE-Dextrano ou DEAE-Dextrano com fosfato de alumínio; carboxipolimetilenos, de preferência o Carbopol®; EMA; emulsões de copolímeros acrílicos, de preferência Neocryl® A640; proteínas de vaccinia ou de vírus de varíola; adjuvantes que sejam partículas subvirais. de preferência o orbivirus; toxina da cólera; brometo de dimetildiocledecilmónio; ou misturas destes, na preparação de uma vacina de Vírus Sincitial Respiratório de Bovinos de dose única, de tal forma que a vacina origine uma imunidade positiva contra a infecção por BRSV após uma única administração.
  2. 2. A utilização de acordo com a reivindicação 1, em que o adjuvante inclua também um tensioactivo.
  3. 3. A utilização de acordo com a reivindicação 2, em que o adjuvante também inclua um tensioactivo presente numa concentração final de cerca de 0,0015 a 0,20 % (em volume).
  4. 4. A utilização de acordo com a reivindicação 2 ou a 3, em que o tensioactivo seja mono-oleato de poli-oxietileno-sorbitano. 3 ΡΕ968722
  5. 5. A utilização de acordo com qualquer uma das reivindicações 1 a 4, em que a vacina também inclua Virus de Rino-traqueite de Bovinos (BHV-IV), Virus de Diarreia de Bovinos (BVDV), e Virus de Parainfluenza 3 (PI-3V). Lisboa, 27 de Agosto de 2007 ι ΡΕ968722 BIBLIOGRAFIA CITADA NA DESCRIÇÃO A lista da bibliografia citada pela requerente destina-se unicamente ao leitor. Ela não integra o documento de patente Europeia. Ainda que se tenha tido grande cuidado na compilação da bibliografia, não se podem excluir erros nem omissões, e o EPO rejeita qualquer responsabilidade a este respeito. Documentos de patentes citados na descrição • EP 129923 A • US 4772466 A • US 5047238 A Outra literatura citada na descrição • KIMMAN e tal. J. Clin. • Vet. Immunol. Immunopathol., 1989, Microbiol., 1987, 25, 1097- 22(2), 145-160. 1106 . • Bovine Respiratory Syncytial Vírus • STOTT et al. J. Hyg. Camb. and the effect of the amount of 1984, 93, 251-261. vírus, vírus replication, route of • THOMAS et al. Agri-Practice, administration and maternal 1986, 5. antibodies, J. Clin. Microbiol., • SYVRUD et al. Vet. Med., 1987, 25(6), 1.097-1.106 1988, 83, 429-430. • Bovine Respiratory Syncytial Virus • Veterinary Pharmaceuticals & infection, and re-infection in cal- Biologicals. 1993, 78, 484, ves with and without maternal anti 740-741, 956-960, 982-983. bodies. Vet Q., 1991, 13(1), 47-59 • Agri-Practice. Vet. Med. • BAKER, Human and Bovine Respiratory Outubro 1983, 78, 1599-1604. Syncytial Virus immunopathologic • Bovine Vet. Fórum 1, 16 de mechanisms. Semin. Immunol. 1990, Fevereiro de 1986, 2. 2(5), 369-374, • SVYRUD et al. Vet. Med., • THOMAS et al., Agri-Practice 7(5), 1988, 429-430 26-30
PT99115633T 1994-05-10 1995-05-08 Vacina viva melhorada contra brsv. PT968722E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24037394A 1994-05-10 1994-05-10

Publications (1)

Publication Number Publication Date
PT968722E true PT968722E (pt) 2007-09-06

Family

ID=22906268

Family Applications (3)

Application Number Title Priority Date Filing Date
PT70083787T PT1820512E (pt) 1994-05-10 1995-05-08 Vacina viva modificada melhorada contra brsv
PT95918442T PT759780E (pt) 1994-05-10 1995-05-08 Vacina melhorada de vsrb vivo modificado
PT99115633T PT968722E (pt) 1994-05-10 1995-05-08 Vacina viva melhorada contra brsv.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT70083787T PT1820512E (pt) 1994-05-10 1995-05-08 Vacina viva modificada melhorada contra brsv
PT95918442T PT759780E (pt) 1994-05-10 1995-05-08 Vacina melhorada de vsrb vivo modificado

Country Status (19)

Country Link
US (2) US5733555A (pt)
EP (4) EP1844791A1 (pt)
JP (3) JP3993230B2 (pt)
KR (1) KR100374434B1 (pt)
CN (1) CN1268393C (pt)
AT (2) ATE195255T1 (pt)
AU (1) AU711350B2 (pt)
BR (1) BR9507717A (pt)
CA (1) CA2189979C (pt)
DE (2) DE69518316T2 (pt)
DK (2) DK0759780T3 (pt)
ES (3) ES2429401T3 (pt)
GR (1) GR3034402T3 (pt)
MY (1) MY111829A (pt)
NZ (1) NZ285324A (pt)
PT (3) PT1820512E (pt)
SI (2) SI0759780T1 (pt)
WO (1) WO1995030437A1 (pt)
ZA (1) ZA953703B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
CZ286632B6 (cs) * 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
EP1462096B1 (en) * 1994-03-07 2008-12-10 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
CA2189979C (en) * 1994-05-10 2011-04-19 Hsien-Jue Chu Improved modified live brsv vaccine
CN1073119C (zh) * 1994-05-18 2001-10-17 吸入治疗系统公司 干扰素干粉配方的方法及组合物
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
AU701753B2 (en) * 1994-10-05 1999-02-04 Vanderbilt University Interleukin-12 as an adjuvant for paramyxoviridae vaccines
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6908618B2 (en) 1997-11-10 2005-06-21 University Of Maryland Production of novel bovine respiratory syncytial viruses from cDNAs
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
TW440845B (en) 1999-08-11 2001-06-16 Ibm Method and system for programming FPGAs on PC-cards without additional hardware
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2002009674A2 (en) * 2000-07-28 2002-02-07 Inhale Therapeutic Systems, Inc. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
BR0209482A (pt) 2001-05-10 2007-01-02 Wyeth Corp composição e método para aumento da densidade celular em culturas de células infectadas com lentivìrus
EP2842569B1 (en) 2001-07-02 2019-04-10 Zoetis Services LLC One dose vaccination with Mycoplasma hyopneumoniae
EP2281572A1 (en) * 2001-07-27 2011-02-09 Wyeth LLC West Nile Vaccine
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
HRP20090271A2 (en) * 2002-08-26 2009-11-30 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
EP1697505A1 (en) * 2003-12-23 2006-09-06 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8097288B1 (en) * 2008-04-16 2012-01-17 Pom Wonderful, Llc Composition and method for providing nutritional immunology for production animals
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
TW200744640A (en) * 2005-08-04 2007-12-16 Wyeth Corp Stabilizers for veterinary vaccines
ES2553253T3 (es) 2005-12-29 2015-12-07 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunogénica de PCV2 para reducir los síntomas clínicos en cerdos
HUE054868T2 (hu) 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
EP1911836A1 (en) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2481420T3 (da) 2006-12-15 2019-05-06 Boehringer Ingelheim Animal Health Usa Inc Enkeltdosis-anti-PCV2-svinevaccine
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR20100113582A (ko) * 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
PT2658570T (pt) * 2010-12-27 2019-02-08 Elanco Us Inc Composições e métodos vacinais contra o vírus da diarreia viral bovina tipo 1b
AR084358A1 (es) 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9649370B2 (en) 2013-05-08 2017-05-16 Protatek International, Inc. Vaccine for PCV2 and mycoplasma
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
JP6778104B2 (ja) 2013-10-02 2020-10-28 ベーリンガー・インゲルハイム・アニマル・ヘルス・ユーエスエー・インコーポレイテッドＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｕｓａ Ｉｎｃ． Ｐｃｖ２ ｏｒｆ２タンパク質変種および前記を含むウイルス様粒子
WO2020033527A2 (en) * 2018-08-07 2020-02-13 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
EP4061303A1 (en) * 2019-11-18 2022-09-28 Elanco Us Inc. Lyophilized cake in straight-walled vial
US11739303B2 (en) 2020-01-24 2023-08-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized NA
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA2189979C (en) * 1994-05-10 2011-04-19 Hsien-Jue Chu Improved modified live brsv vaccine

Also Published As

Publication number Publication date
GR3034402T3 (en) 2000-12-29
JP3993230B2 (ja) 2007-10-17
JP2007137905A (ja) 2007-06-07
EP1820512B1 (en) 2013-07-03
HK1024412A1 (en) 2000-10-13
ES2149361T3 (es) 2000-11-01
MY111829A (en) 2001-01-31
ZA953703B (en) 1996-01-10
DK0759780T3 (da) 2000-11-13
CA2189979C (en) 2011-04-19
NZ285324A (en) 1998-08-26
AU2438795A (en) 1995-11-29
KR100374434B1 (ko) 2003-06-09
JP2011246489A (ja) 2011-12-08
ATE365049T1 (de) 2007-07-15
ES2429401T3 (es) 2013-11-14
DE69535520T2 (de) 2008-02-07
ES2287997T3 (es) 2007-12-16
EP0759780A1 (en) 1997-03-05
CN1152878A (zh) 1997-06-25
BR9507717A (pt) 1997-09-23
PT759780E (pt) 2001-01-31
ATE195255T1 (de) 2000-08-15
US5958423A (en) 1999-09-28
EP1844791A1 (en) 2007-10-17
JPH10500113A (ja) 1998-01-06
DE69518316T2 (de) 2001-03-29
CA2189979A1 (en) 1995-11-16
US5733555A (en) 1998-03-31
PT1820512E (pt) 2013-10-09
EP0968722A1 (en) 2000-01-05
AU711350B2 (en) 1999-10-14
DE69535520D1 (de) 2007-08-02
EP0968722B1 (en) 2007-06-20
CN1268393C (zh) 2006-08-09
EP0759780B1 (en) 2000-08-09
DK0968722T3 (da) 2007-09-24
SI0968722T1 (sl) 2007-10-31
EP1820512A1 (en) 2007-08-22
SI0759780T1 (en) 2000-12-31
DE69518316D1 (de) 2000-09-14
WO1995030437A1 (en) 1995-11-16
KR970703166A (ko) 1997-07-03

Similar Documents

Publication Publication Date Title
PT968722E (pt) Vacina viva melhorada contra brsv.
EP1742659B1 (en) Microfluidized oil-in-water emulsions and vaccine compositions
CA2734654C (en) An immunological composition comprising sulpholipo-cyclodextrin and saponin
HK1024412B (en) Improved modified live brsv vaccine